Efrah Ahmed Ibrahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Efrah Ahmed Ibrahim has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Eray Alper
Department of Nuclear Medicine, Medical Faculty, Bursa Uludag University, Bursa, Turkey
5 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by Springer Nature in Cancer Imaging
- Vol. 26 (1)
When PSMA is not enough: the diagnostic blind spots of PSMA PET/CT and the added value of [¹⁸F]FDG in high-risk prostate cancer: dual-tracer cohort study
PSMA PET/CT has transformed prostate cancer management, yet its diagnostic utility is not absolute. It fails to detect PSMA-suppressed disease variants, including treatment-induced neuroendocrine prostate cancer (t-NEPC) and dedifferentiated tumors, and is inherently blind to second primary malignancies (SPMs). This study evaluated the additional diagnostic yield and direct clinical impact of incorporating [¹⁸F]FDG PET/CT into a systematic, indication-driven dual-tracer protocol in high-risk prostate cancer patients. In this retrospective, STROBE-compliant, single-center cohort study, 82 patients with histologically confirmed prostate cancer who underwent both [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]FDG PET/CT were analyzed. Clinical indications encompassed suspected SPM, suspected dedifferentiation or t-NEPC, initial staging of very high-risk disease, pre-[¹⁷⁷Lu]Lu-PSMA therapy evaluation, and equivocal PSMA findings. The primary endpoint was the proportion of patients in whom [¹⁸F]FDG PET/CT provided additional diagnostic information. Secondary endpoints included concordance analysis and the rate of management changes. Median age was 72 years (IQR 65-75). [⁶⁸Ga]Ga-PSMA-11 demonstrated superior prostate cancer detection compared to [¹⁸F]FDG (70.7% vs. 25.6%; McNemar's p < 0.0001). However, [¹⁸F]FDG PET/CT provided clinically critical additional information and directly altered management in 51.2% of patients (95% CI: 40.6-61.7%). The most impactful contributions were histopathologically confirmed SPM detection (30.5%, predominantly lung and colorectal adenocarcinomas) and identification of PSMA-negative/FDG-positive discordant disease signaling dedifferentiation. No significant correlation was found between PSMA and FDG SUVmax values (Spearman rho = 0.149, p = 0.422), underscoring their biologically distinct and complementary targets. [¹⁸F]FDG PET/CT is not a redundant adjunct to PSMA imaging; it fills a critical diagnostic blind spot. When applied through an indication-driven framework, dual-tracer imaging directly reshapes clinical decision-making in more than half of selected high-risk prostate cancer patients, enabling detection of occult malignancies and guiding pivotal treatment decisions that PSMA PET/CT alone cannot support.
- 2 July 2026
- Published by Springer Nature in Cancer Imaging
- Vol. 26 (1)
Open AccessWhen PSMA is not enough: the diagnostic blind spots of PSMA PET/CT and the added value of [¹⁸F]FDG in high-risk prostate cancer: dual-tracer cohort study
PSMA PET/CT has transformed prostate cancer management, yet its diagnostic utility is not absolute. It fails to detect PSMA-suppressed disease variants, including treatment-induced neuroendocrine prostate cancer (t-NEPC) and dedifferentiated tumors, and is inherently blind to second primary malignancies (SPMs). This study evaluated the additional diagnostic yield and direct clinical impact of incorporating [¹⁸F]FDG PET/CT into a systematic, indication-driven dual-tracer protocol in high-risk prostate cancer patients. In this retrospective, STROBE-compliant, single-center cohort study, 82 patients with histologically confirmed prostate cancer who underwent both [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]FDG PET/CT were analyzed. Clinical indications encompassed suspected SPM, suspected dedifferentiation or t-NEPC, initial staging of very high-risk disease, pre-[¹⁷⁷Lu]Lu-PSMA therapy evaluation, and equivocal PSMA findings. The primary endpoint was the proportion of patients in whom [¹⁸F]FDG PET/CT provided additional diagnostic information. Secondary endpoints included concordance analysis and the rate of management changes. Median age was 72 years (IQR 65-75). [⁶⁸Ga]Ga-PSMA-11 demonstrated superior prostate cancer detection compared to [¹⁸F]FDG (70.7% vs. 25.6%; McNemar's p < 0.0001). However, [¹⁸F]FDG PET/CT provided clinically critical additional information and directly altered management in 51.2% of patients (95% CI: 40.6-61.7%). The most impactful contributions were histopathologically confirmed SPM detection (30.5%, predominantly lung and colorectal adenocarcinomas) and identification of PSMA-negative/FDG-positive discordant disease signaling dedifferentiation. No significant correlation was found between PSMA and FDG SUVmax values (Spearman rho = 0.149, p = 0.422), underscoring their biologically distinct and complementary targets. [¹⁸F]FDG PET/CT is not a redundant adjunct to PSMA imaging; it fills a critical diagnostic blind spot. When applied through an indication-driven framework, dual-tracer imaging directly reshapes clinical decision-making in more than half of selected high-risk prostate cancer patients, enabling detection of occult malignancies and guiding pivotal treatment decisions that PSMA PET/CT alone cannot support.
- 17 June 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
Divergent PET Tracer Avidity in Synchronous Sarcomatoid Carcinoma With Osteosarcomatous Differentiation and Adenocarcinoma of the Prostate
A 76-year-old man with mildly elevated prostate-specific antigen (PSA, 5.44ng/mL) and a PI-RADS 5 lesion on multiparametric MRI underwent dual-tracer PET/CT. 68 Ga-PSMA PET/CT revealed focal intense uptake in one prostatic lobe, while 18 F-FDG PET/CT demonstrated avid uptake in the contralateral lobe. Histopathology confirmed synchronous high-grade prostatic adenocarcinoma (Gleason 9) and sarcomatoid carcinoma with osteosarcomatous differentiation. This discordant dual-tracer pattern highlights the complementary role of PSMA and FDG PET/CT in detecting molecularly divergent synchronous prostatic malignancies.
- 17 June 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
Divergent PET Tracer Avidity in Synchronous Sarcomatoid Carcinoma With Osteosarcomatous Differentiation and Adenocarcinoma of the Prostate
A 76-year-old man with mildly elevated prostate-specific antigen (PSA, 5.44ng/mL) and a PI-RADS 5 lesion on multiparametric MRI underwent dual-tracer PET/CT. 68 Ga-PSMA PET/CT revealed focal intense uptake in one prostatic lobe, while 18 F-FDG PET/CT demonstrated avid uptake in the contralateral lobe. Histopathology confirmed synchronous high-grade prostatic adenocarcinoma (Gleason 9) and sarcomatoid carcinoma with osteosarcomatous differentiation. This discordant dual-tracer pattern highlights the complementary role of PSMA and FDG PET/CT in detecting molecularly divergent synchronous prostatic malignancies.
- Open Access
- 4 June 2026
- Published by Frontiers Media SA in Frontiers in Nuclear Medicine
- Vol. 6, 1825650
Availability, accessibility, and economic feasibility of radionuclide therapies in Africa: a systematic review and quantitative infrastructure analysis
Purpose: Africa faces a projected doubling of cancer burden by 2040, yet access to radionuclide therapies remains critically limited. This systematic review quantifies the availability, accessibility, and economic feasibility of therapeutic nuclear medicine across 54 African nations. Methods: This study combined a PRISMA 2020-compliant systematic literature review with secondary database analysis. A comprehensive search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and African Journals Online (January 2022–March 2026). Epidemiologic and infrastructure data were additionally obtained from GLOBOCAN 2022 and the International Atomic Energy Agency (IAEA). Risk of bias was assessed using the modified Newcastle–Ottawa Scale for peer-reviewed studies and the AACODS checklist for gray literature. Results: Of 2,847 records identified, 47 studies met the inclusion criteria. I-131 therapy for thyroid cancer is available in only 28/54 countries (51.9%), while Lu-177-PSMA for prostate cancer is available in only seven countries (13.0%). Local radiopharmaceutical production reduces therapy costs by 93%–96% compared with imported agents. Africa has approximately 0.18 nuclear medicine physicians per million population vs. 3.1 in Europe. The cost reduction ratio for local vs. imported Lu-177-PSMA is 1:28.3 (US$1,500–3,000 vs. US$42,500). Conclusion: Radionuclide therapy availability in Africa is profoundly inadequate relative to disease burden. Economic modeling demonstrates that local production and regional hub models can achieve cost reductions exceeding 90%, making therapies economically feasible for resource-limited settings. Targeted investment in cyclotron infrastructure and workforce development is urgently needed.
- 4 June 2026
- Published by Frontiers Media SA in Frontiers in Nuclear Medicine
- Vol. 6, 1825650
Open AccessAvailability, accessibility, and economic feasibility of radionuclide therapies in Africa: a systematic review and quantitative infrastructure analysis
Purpose: Africa faces a projected doubling of cancer burden by 2040, yet access to radionuclide therapies remains critically limited. This systematic review quantifies the availability, accessibility, and economic feasibility of therapeutic nuclear medicine across 54 African nations. Methods: This study combined a PRISMA 2020-compliant systematic literature review with secondary database analysis. A comprehensive search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and African Journals Online (January 2022–March 2026). Epidemiologic and infrastructure data were additionally obtained from GLOBOCAN 2022 and the International Atomic Energy Agency (IAEA). Risk of bias was assessed using the modified Newcastle–Ottawa Scale for peer-reviewed studies and the AACODS checklist for gray literature. Results: Of 2,847 records identified, 47 studies met the inclusion criteria. I-131 therapy for thyroid cancer is available in only 28/54 countries (51.9%), while Lu-177-PSMA for prostate cancer is available in only seven countries (13.0%). Local radiopharmaceutical production reduces therapy costs by 93%–96% compared with imported agents. Africa has approximately 0.18 nuclear medicine physicians per million population vs. 3.1 in Europe. The cost reduction ratio for local vs. imported Lu-177-PSMA is 1:28.3 (US$1,500–3,000 vs. US$42,500). Conclusion: Radionuclide therapy availability in Africa is profoundly inadequate relative to disease burden. Economic modeling demonstrates that local production and regional hub models can achieve cost reductions exceeding 90%, making therapies economically feasible for resource-limited settings. Targeted investment in cyclotron infrastructure and workforce development is urgently needed.
- Open Access
- 13 April 2026
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 40 (5) , 469-479
PSMA PET/CT imaging for biochemical recurrence in prostate cancer: can it replace conventional imaging and guide salvage therapy?
Biochemical recurrence (BCR) after primary treatment for prostate cancer presents a significant clinical challenge. Conventional imaging modalities have limited sensitivity for detecting sites of recurrence, particularly at low prostate specific antigen (PSA) levels. Prostate specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) has emerged as a promising diagnostic tool that may transform the management paradigm for recurrent prostate cancer. To systematically evaluate the diagnostic performance of PSMA PET/CT in patients with biochemical recurrence of prostate cancer, compare it with conventional imaging modalities, and assess its impact on salvage therapy decisions. A systematic review was conducted following the PRISMA guidelines. PubMed/MEDLINE, Embase, Cochrane Library, and Web of Science were searched for studies published between 2020 and 2025. Studies evaluating PSMA PET/CT in patients with biochemical recurrence after primary treatment were included. The primary outcomes were detection rates stratified by PSA levels, diagnostic accuracy compared to conventional imaging, and the impact on management decisions. PSMA PET/CT demonstrated superior detection rates compared to conventional imaging across all PSA levels, with detection rates ranging from 36.2% to 96.7% for PSA levels below 0.5 ng/mL and above 5 ng/mL, respectively. In patients with negative conventional imaging, PSMA PET/CT identified true positive lesions in 64% of cases (95% CI, 56.7%-71.5%). Among patients with high-risk biochemically recurrent prostate cancer and negative conventional imaging, PSMA PET/CT detected distant metastatic disease (M1) in 46% of patients. Management plans were altered in 54-76% of cases based on PSMA PET/CT findings, with significant implications for salvage therapy targeting. PSMA PET/CT significantly outperforms conventional imaging in detecting sites of recurrence across all PSA levels, with particularly notable advantages at low PSA values. The high detection rates and accuracy of PSMA PET/CT in patients with negative conventional imaging support its role as a replacement for or complement to standard imaging protocols, while acknowledging current limitations in availability, cost, and long-term outcome data. PSMA PET/CT findings frequently alter management decisions, enabling more precise targeting of salvage therapies and potentially improving oncological outcomes.
- 13 April 2026
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 40 (5) , 469-479
Open AccessPSMA PET/CT imaging for biochemical recurrence in prostate cancer: can it replace conventional imaging and guide salvage therapy?
Biochemical recurrence (BCR) after primary treatment for prostate cancer presents a significant clinical challenge. Conventional imaging modalities have limited sensitivity for detecting sites of recurrence, particularly at low prostate specific antigen (PSA) levels. Prostate specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) has emerged as a promising diagnostic tool that may transform the management paradigm for recurrent prostate cancer. To systematically evaluate the diagnostic performance of PSMA PET/CT in patients with biochemical recurrence of prostate cancer, compare it with conventional imaging modalities, and assess its impact on salvage therapy decisions. A systematic review was conducted following the PRISMA guidelines. PubMed/MEDLINE, Embase, Cochrane Library, and Web of Science were searched for studies published between 2020 and 2025. Studies evaluating PSMA PET/CT in patients with biochemical recurrence after primary treatment were included. The primary outcomes were detection rates stratified by PSA levels, diagnostic accuracy compared to conventional imaging, and the impact on management decisions. PSMA PET/CT demonstrated superior detection rates compared to conventional imaging across all PSA levels, with detection rates ranging from 36.2% to 96.7% for PSA levels below 0.5 ng/mL and above 5 ng/mL, respectively. In patients with negative conventional imaging, PSMA PET/CT identified true positive lesions in 64% of cases (95% CI, 56.7%-71.5%). Among patients with high-risk biochemically recurrent prostate cancer and negative conventional imaging, PSMA PET/CT detected distant metastatic disease (M1) in 46% of patients. Management plans were altered in 54-76% of cases based on PSMA PET/CT findings, with significant implications for salvage therapy targeting. PSMA PET/CT significantly outperforms conventional imaging in detecting sites of recurrence across all PSA levels, with particularly notable advantages at low PSA values. The high detection rates and accuracy of PSMA PET/CT in patients with negative conventional imaging support its role as a replacement for or complement to standard imaging protocols, while acknowledging current limitations in availability, cost, and long-term outcome data. PSMA PET/CT findings frequently alter management decisions, enabling more precise targeting of salvage therapies and potentially improving oncological outcomes.
- Open Access
- 25 March 2026
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 25 (1) , 93-100
FDG PET/CT as the Decisive Modality in Distinguishing Clear Cell Sarcoma from Melanoma When Immunohistochemistry Overlaps: A Case Report
Clear cell sarcoma (CCS) and malignant melanoma share overlapping immunohistochemical profiles, particularly SOX10 and HMB45 positivity, making histopathological differentiation challenging. Distinguishing between these entities is clinically essential due to their differing prognoses and therapeutic approaches. This case highlights how fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) contributed decisively to establishing the diagnosis of CCS by following a pathologist-recommended diagnostic algorithm. A 70-year-old male presented with a progressively enlarging left scapular mass. Tru-cut biopsy revealed a malignant neoplasm positive for SOX10 and HMB45, with immunohistochemistry insufficient to differentiate CCS from metastatic melanoma. The pathology report recommended a search for a primary cutaneous melanoma, indicating that in the absence of such a lesion, the diagnosis should favor CCS. Whole-body 18F-FDG PET/CT demonstrated extensive metastatic disease involving the lungs, left adrenal gland, T11 vertebra, scapula, and a large presacral mass. Critically, no hypermetabolic cutaneous, mucosal, or nodal lesions suggestive of a primary melanoma were identified. Comprehensive dermatological evaluation was also negative for suspicious melanocytic lesions. Based on the diagnostic algorithm, histopathology, plus exclusion of a primary melanoma, the PET/CT findings supported the diagnosis of metastatic CCS. This case demonstrates that 18F-FDG PET/CT can serve as a diagnostic tool when histopathology alone is inconclusive. The absence of a primary melanoma on whole-body 18F-FDG PET/CT and clinical examination was the decisive factor favoring CCS over melanoma of unknown primary. This case underscores the limitations of MRI, which often describes CCS as a well-defined, benign-appearing mass, potentially delaying accurate diagnosis. E.A.I. contributed to the conception and design of the case report, performed the literature review, analyzed and interpreted the PET/CT imaging findings, prepared the initial manuscript draft, and completed all subsequent revisions. E.A. provided senior clinical oversight, verified the diagnostic interpretation, contributed to critical revision of the manuscript for important intellectual content, and approved the final version for submission. Both authors read and approved the final manuscript. This case report was conducted in accordance with the ethical standards of our institutional review board. Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. All data generated or analyzed during this case report are included in this published article. Article published online: 25 March 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 25 March 2026
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 25 (1) , 93-100
Open AccessFDG PET/CT as the Decisive Modality in Distinguishing Clear Cell Sarcoma from Melanoma When Immunohistochemistry Overlaps: A Case Report
Clear cell sarcoma (CCS) and malignant melanoma share overlapping immunohistochemical profiles, particularly SOX10 and HMB45 positivity, making histopathological differentiation challenging. Distinguishing between these entities is clinically essential due to their differing prognoses and therapeutic approaches. This case highlights how fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) contributed decisively to establishing the diagnosis of CCS by following a pathologist-recommended diagnostic algorithm. A 70-year-old male presented with a progressively enlarging left scapular mass. Tru-cut biopsy revealed a malignant neoplasm positive for SOX10 and HMB45, with immunohistochemistry insufficient to differentiate CCS from metastatic melanoma. The pathology report recommended a search for a primary cutaneous melanoma, indicating that in the absence of such a lesion, the diagnosis should favor CCS. Whole-body 18F-FDG PET/CT demonstrated extensive metastatic disease involving the lungs, left adrenal gland, T11 vertebra, scapula, and a large presacral mass. Critically, no hypermetabolic cutaneous, mucosal, or nodal lesions suggestive of a primary melanoma were identified. Comprehensive dermatological evaluation was also negative for suspicious melanocytic lesions. Based on the diagnostic algorithm, histopathology, plus exclusion of a primary melanoma, the PET/CT findings supported the diagnosis of metastatic CCS. This case demonstrates that 18F-FDG PET/CT can serve as a diagnostic tool when histopathology alone is inconclusive. The absence of a primary melanoma on whole-body 18F-FDG PET/CT and clinical examination was the decisive factor favoring CCS over melanoma of unknown primary. This case underscores the limitations of MRI, which often describes CCS as a well-defined, benign-appearing mass, potentially delaying accurate diagnosis. E.A.I. contributed to the conception and design of the case report, performed the literature review, analyzed and interpreted the PET/CT imaging findings, prepared the initial manuscript draft, and completed all subsequent revisions. E.A. provided senior clinical oversight, verified the diagnostic interpretation, contributed to critical revision of the manuscript for important intellectual content, and approved the final version for submission. Both authors read and approved the final manuscript. This case report was conducted in accordance with the ethical standards of our institutional review board. Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. All data generated or analyzed during this case report are included in this published article. Article published online: 25 March 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 18 February 2026
- Published by Elsevier in Journal of Medical Imaging and Radiation Sciences
- Vol. 57 (3) , 102199
The evolving role of [¹⁸F]FDG PET/CT in reducing or replacing biopsy in selected malignancies: A narrative literature review
- 18 February 2026
- Published by Elsevier in Journal of Medical Imaging and Radiation Sciences
- Vol. 57 (3) , 102199
The evolving role of [¹⁸F]FDG PET/CT in reducing or replacing biopsy in selected malignancies: A narrative literature review
- Open Access
- 21 January 2026
- Published by Springer Nature in EJNMMI Research
- Vol. 16 (1)
Beyond discovery: are we understanding PET tracers as fast as we invent them? a critical review
The field of nuclear medicine is experiencing an unprecedented proliferation of novel positron emission tomography (PET) tracers, with FDA-approved PET tra
- 21 January 2026
- Published by Springer Nature in EJNMMI Research
- Vol. 16 (1)
Open AccessBeyond discovery: are we understanding PET tracers as fast as we invent them? a critical review
The field of nuclear medicine is experiencing an unprecedented proliferation of novel positron emission tomography (PET) tracers, with FDA-approved PET tra
- Open Access
- 1 December 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine Open
- Vol. 2 (4)
Liver Cancer Discovered Through Leg Pain
A 71-year-old man with no history of liver disease presented with progressive left leg pain. Imaging revealed a destructive tibial lesion, but the initial biopsy was inconclusive. Whole body 18 F-FDG PET/CT demonstrated moderate metabolic activity in the tibial mass and mild uptake in an unsuspected hepatic lesion. Repeated biopsy confirmed metastatic hepatocellular carcinoma in the tibia and primary HCC in the liver. This case illustrates tibial metastasis as the initial clinical manifestation of occult HCC and underscores the value of PET/CT in detecting synchronous primary and metastatic disease.
- 1 December 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine Open
- Vol. 2 (4)
Open AccessLiver Cancer Discovered Through Leg Pain
A 71-year-old man with no history of liver disease presented with progressive left leg pain. Imaging revealed a destructive tibial lesion, but the initial biopsy was inconclusive. Whole body 18 F-FDG PET/CT demonstrated moderate metabolic activity in the tibial mass and mild uptake in an unsuspected hepatic lesion. Repeated biopsy confirmed metastatic hepatocellular carcinoma in the tibia and primary HCC in the liver. This case illustrates tibial metastasis as the initial clinical manifestation of occult HCC and underscores the value of PET/CT in detecting synchronous primary and metastatic disease.